JP2004506658A5 - - Google Patents

Download PDF

Info

Publication number
JP2004506658A5
JP2004506658A5 JP2002519615A JP2002519615A JP2004506658A5 JP 2004506658 A5 JP2004506658 A5 JP 2004506658A5 JP 2002519615 A JP2002519615 A JP 2002519615A JP 2002519615 A JP2002519615 A JP 2002519615A JP 2004506658 A5 JP2004506658 A5 JP 2004506658A5
Authority
JP
Japan
Prior art keywords
use according
muscle
vegf
gene encoding
delivered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002519615A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004506658A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2001/001902 external-priority patent/WO2002014487A2/en
Publication of JP2004506658A publication Critical patent/JP2004506658A/ja
Publication of JP2004506658A5 publication Critical patent/JP2004506658A5/ja
Pending legal-status Critical Current

Links

JP2002519615A 2000-08-17 2001-08-17 アデノ随伴ウイルスを介した血管形成因子のデリバリー Pending JP2004506658A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22605600P 2000-08-17 2000-08-17
PCT/IB2001/001902 WO2002014487A2 (en) 2000-08-17 2001-08-17 Adeno-associated virus-mediated delivery of angiogenic factors

Publications (2)

Publication Number Publication Date
JP2004506658A JP2004506658A (ja) 2004-03-04
JP2004506658A5 true JP2004506658A5 (cg-RX-API-DMAC7.html) 2008-10-09

Family

ID=22847367

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002519615A Pending JP2004506658A (ja) 2000-08-17 2001-08-17 アデノ随伴ウイルスを介した血管形成因子のデリバリー

Country Status (9)

Country Link
US (2) US20020111324A1 (cg-RX-API-DMAC7.html)
EP (1) EP1311699B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004506658A (cg-RX-API-DMAC7.html)
AT (1) ATE366319T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001294096A1 (cg-RX-API-DMAC7.html)
CA (1) CA2419245A1 (cg-RX-API-DMAC7.html)
DE (1) DE60129229T2 (cg-RX-API-DMAC7.html)
ES (1) ES2288993T3 (cg-RX-API-DMAC7.html)
WO (1) WO2002014487A2 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2406687A1 (en) * 2001-11-09 2003-05-09 Transgene S.A. Chimeric promoters for controlling expression in muscle cells
WO2003080116A1 (en) * 2002-03-21 2003-10-02 University Of Florida Modulating angiogenesis
US20030198620A1 (en) * 2002-04-16 2003-10-23 Keiya Ozawa Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions
CN100387723C (zh) * 2005-12-02 2008-05-14 浙江大学 血管生长素基因重组腺相关病毒载体及制备方法和用途
GB0821834D0 (en) * 2008-11-28 2009-01-07 Iti Scotland Ltd Calibration and control method
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
EP3215191B1 (en) 2014-11-05 2024-08-14 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
EP3242605A4 (en) * 2015-01-06 2018-08-29 CardioVascular BioTherapeutics, Inc. Angiogenic treatment of ischemic heart disease
CA2976675A1 (en) 2015-02-16 2016-08-25 Cardiovascular Biotherapeutics, Inc. Therapeutic angiogenesis for treating erectile conditions
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
IL297576B2 (en) 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
EP3831281B1 (en) 2016-08-30 2026-02-25 The Regents of The University of California Devices and systems for biomedical targeting and delivery
MX2019013172A (es) 2017-05-05 2020-09-07 Voyager Therapeutics Inc Composiciones y metodos para tratar la enfermedad de huntington.
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
CN112424359A (zh) 2018-05-15 2021-02-26 沃雅戈治疗公司 用于治疗帕金森氏病的组合物和方法
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
BR112023001456A2 (pt) 2020-07-27 2023-04-11 Voyager Therapeutics Inc Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
US20230285596A1 (en) 2020-07-27 2023-09-14 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
US20250049955A1 (en) 2021-11-17 2025-02-13 Voyager Therapeutics, Inc. Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
AU2023427408A1 (en) 2023-02-02 2025-09-04 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0764893A (ja) * 1993-08-31 1995-03-10 Canon Inc ネットワーク・システム
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US6162796A (en) * 1995-09-27 2000-12-19 The Rockefeller University Method for transferring genes to the heart using AAV vectors
US6004797A (en) * 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
US5858351A (en) * 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
EP0906440A1 (en) * 1996-03-04 1999-04-07 Targeted Genetics Corporation Methods for transducing cells in blood vessels using recombinant aav vectors
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
CN1295617A (zh) * 1998-02-06 2001-05-16 科莱特诺医疗公司 血管生成因子-血管内皮细胞生长因子vegf的突变体
EP1139751A4 (en) * 1998-12-28 2003-03-19 Arch Dev Corp EFFICIENT AND STABLE -I (IN VIVO) GENE TRANSFER TO CARDIOMYCETS USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS
EP1016726A1 (en) * 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
EP1183358A1 (en) * 1999-06-07 2002-03-06 Edwards Lifesciences Corporation Targeted angiogenesis
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder

Similar Documents

Publication Publication Date Title
EP1311699B1 (en) Adeno-associated virus-mediated delivery of angiogenic factors
FI3717636T3 (fi) Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä
JP2021503914A5 (cg-RX-API-DMAC7.html)
US6753321B2 (en) Method of modulating neovascularization
JP2005501802A5 (cg-RX-API-DMAC7.html)
EP4488287A3 (en) Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy
US20170252405A1 (en) Method to induce neovascular formation and tissue regeneration
Su et al. Additive effect of AAV-mediated angiopoietin-1 and VEGF expression on the therapy of infarcted heart
US7524493B2 (en) Nucleic acid constructs cells transformed therewith and methods utilizing same for inducing liver regeneration and alleviation of portal hypertension
US6329348B1 (en) Method of inducing angiogenesis
US20070232541A1 (en) Methods of regulating angiogenisis through stabilization of pedf
JP2002533359A5 (cg-RX-API-DMAC7.html)
JPWO2022186282A5 (cg-RX-API-DMAC7.html)
EP1581241A2 (en) Stimulation of vascularization with vegf-b
Sellner et al. Generation of efficient human blood progenitor–targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells
JP2019070001A (ja) 肝細胞増殖因子及びストローマ細胞由来因子1αを用いた末梢動脈疾患の予防または治療用組成物
JP2009517343A5 (cg-RX-API-DMAC7.html)
JP2021513871A5 (cg-RX-API-DMAC7.html)
WO2023111106A1 (en) Fukutin related protein gene transfer increase using modified itr sequences
WO2014159546A1 (en) Modified soluble vegf receptor-1 genes and vectors for gene therapy
WO1999048537A1 (en) Use of scatter factor to enhance angiogenesis
EP4198048A1 (en) Calpain-3 gene transfer increase using modified itr sequences
Kizana Therapeutic prospects of cardiac gene transfer
EP1870473A1 (en) Adeno-associated virus-mediated delivery of angiogenic factors
JP2021527418A (ja) ジストログリカノパチーおよびラミニン欠損筋ジストロフィーを治療するための組換えアデノ随伴ウイルス生成物および方法